South Korea will require travelers from China to show either a negative PCR or antigen test for the coronavirus before boarding flights to the country by March, according to Prime Minister Han Duck-soo.
All travelers from China should receive a PCR test within 48 hours or an antigen test within 24 hours before their arrival.
They will also be required to receive a PCR test on the first day of their arrival.
South Korea will also restrict issuing short-term visas for Chinese nationals, excluding diplomats, public officials, and essential business and humanitarian purposes, The visa restriction will be applied by February.
In addition, South Korea will temporarily stop expanding flights to China, and all flights from China will be required to arrive at Incheon International Airport for proper containment management.
South Korea is facing a “twindemic” of the flu and the coronavirus.


US Auto Industry Urges Trump to Block Chinese EV Market Access
CSL Shares Crash as Profit Warning and $5 Billion Impairment Shake Investors
China Inflation Jumps as Iran Conflict Drives Energy Costs Higher
CDC Acting Director Urges Measles Vaccination as U.S. Cases Surge in 2026
Armani Group Eyes Strategic Stake Sale to Luxury Giants
Locked up then locked out: how NZ’s bank rules make life for ex-prisoners even harder
Coinbase Q1 2026 Earnings Miss Sends COIN Stock Lower Amid Crypto Market Slump
Rubio Discusses Iran Crisis and Strait of Hormuz Disruptions With UK and Australia
Heritage, desire and diplomacy: why China still values scotch whisky
The ghost of Robodebt – Federal Court rules billions of dollars in welfare debts must be recalculated
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
Orsted Q1 EBITDA Beats Expectations Despite U.S. Impairments
Britain has almost 1 million young people not in work or education – here’s what evidence shows can change that
The pandemic is still disrupting young people’s careers
Novocure Stock Surges 30% After FDA Approves Optune Pax for Pancreatic Cancer Treatment
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval
Nike Tariff Refund Lawsuit Sparks Consumer Backlash Over Price Increases 



